| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $287,368 | 4 | 100 |
Sells | $0 | 0 | 0 |
| MICHEL GERARD J | CHIEF EXECUTIVE OFFICER | 2 | $198,358 | 0 | $0 | $198,358 |
| Pennell Sandra | Chief Financial Officer | 1 | $50,018 | 0 | $0 | $50,018 |
| Sylvester John Richard | director | 1 | $38,992 | 0 | $0 | $38,992 |
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to …
Over the last 12 months, insiders at Delcath Systems, Inc. have bought $287,368 and sold $0 worth of Delcath Systems, Inc. stock.
On average, over the past 5 years, insiders at Delcath Systems, Inc. have bought $606,252 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: MICHEL GERARD J (CHIEF EXECUTIVE OFFICER) — $198,358. Pennell Sandra (Chief Financial Officer) — $50,018. Sylvester John Richard (director) — $38,992.
The last purchase of 5,533 shares for transaction amount of $50,018 was made by Pennell Sandra (Chief Financial Officer) on 2026‑03‑06.
| 2026-03-06 | Pennell Sandra | Chief Financial Officer | 5,533 0.0159% | $9.04 | $50,018 | +38.00% | ||
| 2026-03-02 | MICHEL GERARD J | CHIEF EXECUTIVE OFFICER | 11,200 0.0325% | $8.96 | $100,309 | +37.96% | ||
| 2025-11-21 | Sylvester John Richard | director | 4,386 0.0125% | $8.89 | $38,992 | +22.66% | ||
| 2025-11-11 | MICHEL GERARD J | CHIEF EXECUTIVE OFFICER | 11,500 0.0327% | $8.53 | $98,049 | +26.57% | ||
| 2024-03-19 | SALAMON STEVEN A J | director | 26,882 0.106% | $3.72 | $100,001 | +110.63% | ||
| 2024-03-19 | Aharon Gil | director | 26,882 0.106% | $3.72 | $100,001 | +110.63% | ||
| 2023-12-12 | Vukovic Vojo | Chief Medical Officer | 40,000 0.1728% | $3.00 | $120,000 | +140.73% | ||
| 2023-12-08 | MICHEL GERARD J | Chief Executive Officer | 34,000 0.1516% | $2.94 | $99,960 | +150.00% | ||
| 2023-11-17 | Rosalind Advisors, Inc. | director | 100,000 0.6437% | $2.40 | $240,410 | +175.31% | ||
| 2023-11-17 | Pennell Sandra | SVP of Finance, PFO and PAO | 30,000 0.1952% | $2.43 | $72,900 | +175.31% | ||
| 2023-11-16 | Vukovic Vojo | Chief Medical Officer | 60,000 0.3928% | $2.48 | $148,800 | +172.47% | ||
| 2023-11-16 | Hoffman David L. | See Remarks | 40,000 0.2618% | $2.48 | $99,200 | +172.47% | ||
| 2023-10-13 | Purpura John | Chief Operating Officer | 14,505 0.0944% | $3.44 | $49,897 | +44.51% | ||
| 2023-08-21 | Sylvester John Richard | director | 10,550 0.093% | $4.80 | $50,640 | -8.86% | ||
| 2023-03-29 | MICHEL GERARD J | Chief Executive Officer | 19,646 0.0001% | $4.84 | $95,087 | -19.86% | ||
| 2022-12-14 | Rosalind Advisors, Inc. | director | 15,215 0.1678% | $3.62 | $55,045 | +26.22% | ||
| 2022-12-14 | SALAMON STEVEN A J | director | 15,215 0.1678% | $3.62 | $55,045 | +26.22% | ||
| 2022-12-13 | MICHEL GERARD J | Chief Executive Officer | 51,725 0.4573% | $2.90 | $150,003 | +26.22% | ||
| 2022-07-20 | MICHEL GERARD J | Chief Executive Officer | 62,814 0.6782% | $3.98 | $250,000 | +7.50% | ||
| 2022-05-16 | Purpura John | Chief Operating Officer | 3,300 0.0396% | $4.61 | $15,213 | -13.01% |
| MICHEL GERARD J | CHIEF EXECUTIVE OFFICER | 342034 0.9857% | $4.93M | 13 | 0 | <0.0001% |
| Pennell Sandra | Chief Financial Officer | 77018 0.222% | $1.11M | 2 | 0 | +175.31% |
| Sylvester John Richard | director | 14936 0.043% | $215,078.40 | 2 | 0 | <0.0001% |
| SALAMON STEVEN A J | director | 1121025 3.2307% | $16.14M | 14 | 0 | <0.0001% |
| Aharon Gil | director | 1069710 3.0828% | $15.4M | 3 | 0 | +23.8% |
| Rosalind Advisors, Inc. | director | 1038828 2.9938% | $14.96M | 12 | 0 | <0.0001% |
| LADD ROBERT | director | 631294 1.8194% | $9.09M | 48 | 11 | |
| Taglietti Marco | director | 220000 0.634% | $3.17M | 2 | 0 | |
| Philips Laura A | director | 205299 0.5917% | $2.96M | 8 | 0 | |
| HOBBS EAMONN P | President and CEO | 162000 0.4669% | $2.33M | 2 | 0 | |
| Taney Richard | Chief Executive Officer | 161000 0.464% | $2.32M | 5 | 0 | |
| HERSCHKOWITZ SAMUEL /FA/ | Chief Operating Officer | 160375 0.4622% | $2.31M | 2 | 10 | |
| Koplewicz Harold S | director | 148521 0.428% | $2.14M | 5 | 0 | |
| Vukovic Vojo | Chief Medical Officer | 100000 0.2882% | $1.44M | 2 | 0 | +156.6% |
| WATSON DOUGLAS G | director | 61369 0.1769% | $883,713.60 | 1 | 0 | |
| Miao Graham G | Exec. V.P., CFO | 54000 0.1556% | $777,600.00 | 1 | 0 | |
| Purpura John | Chief Operating Officer | 41526 0.1197% | $597,974.40 | 7 | 0 | <0.0001% |
| Hoffman David L. | See Remarks | 40000 0.1153% | $576,000.00 | 1 | 0 | +172.47% |
| LEUNG GABRIEL | director | 15847 0.0457% | $228,196.80 | 1 | 0 | |
| Rueckert William Dodge | director | 7926 0.0228% | $114,134.40 | 3 | 0 | |
| Keck Barbra | Chief Financial Officer | 7500 0.0216% | $108,000.00 | 3 | 0 | |
| Simpson Jennifer K. | President & CEO | 7500 0.0216% | $108,000.00 | 3 | 0 | |
| STOLL ROGER G PHD | director | 5901 0.017% | $84,974.40 | 5 | 0 |
| Increased Positions | 63 | +46.67% | 2M | +12.21% |
| Decreased Positions | 55 | -40.74% | 3M | -17.15% |
| New Positions | 20 | New | 827,308 | New |
| Sold Out Positions | 19 | Sold Out | 2M | Sold Out |
| Total Postitions | 143 | +5.93% | 17M | -4.94% |
| Rosalind Advisors, Inc. | $32,839.00 | 9.43% | 3.3M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $17,601.00 | 5.05% | 1.77M | +51,757 | +3.01% | 2025-09-30 |
| Vanguard Group Inc | $16,491.00 | 4.74% | 1.66M | +46,693 | +2.9% | 2025-09-30 |
| Geode Capital Management, Llc | $6,842.00 | 1.97% | 687,613 | -15,558 | -2.21% | 2025-09-30 |
| Nantahala Capital Management, Llc | $6,631.00 | 1.9% | 666,435 | +666,435 | New | 2025-09-30 |
| State Street Corp | $6,181.00 | 1.78% | 621,250 | +147,357 | +31.09% | 2025-09-30 |
| Vivo Capital, Llc | $5,667.00 | 1.63% | 569,526 | 0 | 0% | 2025-09-30 |
| Divisadero Street Capital Management, Lp | $4,738.00 | 1.36% | 476,160 | +476,160 | New | 2025-09-30 |
| Citadel Advisors Llc | $4,471.00 | 1.28% | 449,315 | -353,893 | -44.06% | 2025-09-30 |
| Propel Bio Management, Llc | $4,363.00 | 1.25% | 438,509 | +212,457 | +93.99% | 2025-09-30 |